论文部分内容阅读
目的万爽力(曲美他嗪)是一种新型的抗心肌缺血的药物,能够改善患者的运动耐量和心肌的直接保护作用同时并没有血流动力学效应。但目前对于严重缺血性心肌病患者的临床治疗价值还需要进一步观察。方法 20例岁确诊为缺血性心肌病(左心室射血分数<40%)的患者在常规治疗的基础上加用每日60mg万爽力治疗5个月,随诊观察患者临床情况以及超声心动图指标的变化。结果 20例患者均可耐受在常规治疗基础上加用每日60mg万爽力的治疗,随诊发现患者心绞痛发作明显减少,运动耐量(NYHA分级)明显改善。同时患者心率、收缩压、心率血压乘积、左心室射血分数、左心室容量以及整体室壁运动指数无明显改变。结论缺血性心肌病的患者在常规治疗基础上加用万爽力是安全的,同时其能明显改善患者的临床状态,而这种作用并不改变心肌氧的供求比值。
Purpose Wanzhuang Li (trimetazidine) is a new anti-myocardial ischemia drugs, can improve patient’s exercise tolerance and myocardial direct protection without hemodynamic effects. However, the clinical value of patients with severe ischemic cardiomyopathy needs further observation. Methods Twenty patients with diagnosed as ischemic cardiomyopathy (left ventricular ejection fraction <40%) were treated with 60 mg Wanzhuang force daily for 5 months on the basis of routine treatment. The clinical and ultrasonography Cardiogram changes in indicators. Results All the 20 patients were able to tolerate the 60 mg QWL daily treatment on the basis of conventional treatment. The incidence of angina pectoris was significantly decreased and the exercise tolerance (NYHA classification) was significantly improved. At the same time, the patients heart rate, systolic blood pressure, heart rate blood pressure product, left ventricular ejection fraction, left ventricular volume and overall wall motion index no significant change. Conclusions Patients with ischemic cardiomyopathy are safe on the basis of conventional treatment, and at the same time, they can significantly improve the clinical status of patients, and this effect does not change the ratio of myocardial oxygen supply and demand.